Skip to main content

Table 3 Stratified analysis of BCSS in the matched cohort

From: Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy?

Variable Surgical axillary staging Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Age (years)
 18–49 No Ref.   Ref.  
Yes 0.49 (0.27–0.90) 0.021 0.45 (0.24–0.86) 0.015
 50–64 No Ref.   Ref.  
Yes 0.79 (0.51–1.22) 0.289 0.82 (0.53–1.27) 0.374
 65–79 No Ref.   Ref.  
Yes 0.80 (0.61–1.06) 0.116 0.78 (0.59–1.02) 0.070
 80– No Ref.   Ref.  
Yes 0.67 (0.50–0.91) 0.010 0.64 (0.47–0.86) 0.004
T stage
 T1mic No Ref.   Ref.  
Yes 1.01 (0.38–2.68) 0.989 0.94 (0.35–2.53) 0.906
 T1a No Ref.   Ref.  
Yes 0.74 (0.42–1.30) 0.290 0.73 (0.42–1.30) 0.288
 T1b No Ref.   Ref.  
Yes 0.74 (0.52–1.05) 0.090 0.72 (0.51–1.03) 0.069
 T1c No Ref.   Ref.  
Yes 0.70 (0.56–0.88) 0.002 0.67 (0.54–0.84) 0.001
Grade
 I No Ref.   Ref.  
Yes 0.98 (0.66–1.45) 0.918 0.98 (0.66–1.46) 0.933
 II No Ref.   Ref.  
Yes 0.77 (0.59–1.01) 0.056 0.74 (0.57–0.97) 0.029
 III No Ref.   Ref.  
Yes 0.51 (0.36–0.71) < 0.001 0.49 (0.35–0.68) < 0.001
 Unknown No Ref.   Ref.  
Yes 0.98 (0.52–1.83) 0.936 0.92 (0.49–1.72) 0.791
Histological type
 Ductal No Ref.   Ref.  
Yes 0.75 (0.62–0.92) 0.005 0.72 (0.59–0.88) 0.001
 Lobular No Ref.   Ref.  
Yes 0.62 (0.38–0.97) 0.045 0.63 (0.39–0.99) 0.048
 Favorable No Ref.   Ref.  
Yes 0.96 (0.50–1.84) 0.896 0.91 (0.47–1.75) 0.777
 Others No Ref.   Ref.  
Yes 0.28 (0.06–1.38) 0.118 0.29 (0.06–1.41) 0.124
  1. BCSS breast cancer-specific survival, HR hazard ratios, CI confidence intervals